Drug intelligence / Profile preview

SKL37221

Development stage: Preclinical
Lead developer: SK Life Science
Modality: Small Molecules

Overview

SKL37221 is a small-molecule ligand developed by WARF Therapeutics that targets the prostate-specific membrane antigen (PSMA). It is designed for the imaging and/or targeted therapy of prostate cancer. By binding specifically to PSMA, which is highly overexpressed in prostate cancer cells, the molecule can deliver diagnostic or therapeutic payloads directly to the tumor site. As of early 2026, the program is in the IND-enabling (IND Studies) stage of development, aiming to transition into clinical trials for the treatment and detection of prostate cancer.

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on SKL37221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKL37221.

Explore the full profile